Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.68 |
| ▸ | CNR2 | P34972 | 4/20 | 0.54 |
| ▸ | TACR2 | P21452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525029 | 0.87 | CNR1 (0.68) | CNR1CNR2TACR2 | |
| SCHEMBL6524755 | 0.87 | CNR1 (0.68) | CNR1CNR2TACR2 | |
| SCHEMBL6527450 | 0.87 | CNR1 (0.68) | CNR1CNR2TACR2 | |
| SCHEMBL1376720 | 0.82 | CNR1 (0.84) | CNR1CNR2TACR2 | |
| SCHEMBL1376977 | 0.82 | CNR1 (0.84) | CNR1CNR2TACR2 | |
| SCHEMBL5347341 | 0.82 | CNR1 (0.84) | CNR1CNR2TACR2 | |
| SCHEMBL1376443 | 0.81 | CNR1 (1.00) | CNR1CNR2TACR2 | |
| SCHEMBL9932180 | 0.81 | CNR1 (1.00) | CNR1CNR2TACR2 | |
| SCHEMBL5274947 | 0.81 | CNR1 (1.00) | CNR1CNR2TACR2 | |
| SCHEMBL1491756 | 0.80 | CNR1 (0.83) | CNR1CNR2TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227491-B2 | 5-(3,4-dichloro-phenyl)-N-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110065759-A1 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY)-NICOTINAMIDE AND SALTS THEREOF | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065759-A1 | 5-(3,4-DICHLORO-PHENYL)-N-(2-HYDROXY-CYCLOHEXYL)-6-(2,2,2-TRIFLUORO-ETHOXY)-NICOTINAMIDE AND SALTS THEREOF | NNT, PCSK9, NADK | CNR1 679/4885CNR2 299/4885TACR2 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.